The March towards a Vaccine for Congenital CMV: Rationale and Models

PLoS Pathogens

Volumn 12, Issue 2, 2016, Pages

  Bialas, Kristy M ^a   Permar, Sallie R ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; INTERLEUKIN 12; NEUTRALIZING ANTIBODY;

CELLULAR IMMUNITY; COGNITIVE DEFECT; CONGENITAL CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG RESEARCH; HEARING IMPAIRMENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PREGNANCY; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS LOAD; VIRUS TRANSMISSION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODEL; FEMALE; GUINEA PIG; IMMUNOLOGY; NEWBORN;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HUMANS; INFANT, NEWBORN; PREGNANCY; VACCINATION;

EID: 84959541899     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005355     Document Type: Review

References (20)

1. Schleiss M. R., Heineman T. C., 2005. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines4:381–406. 16026251
2. Boppana S. B., Ross S. A., Fowler K. B., 2013. Congenital cytomegalovirus infection: clinical outcome. Clin Infect Dis57: Suppl 4S178–S181. doi: 10.1093/cid/cit62924257422
3. Lilleri D, Fornara C., Furione M., Zavattoni M., Revello M.G., Gerna G, 2007. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus.J Infect Dis195: 1062–1070. doi: 10.1086/51224517330798
4. Boppana S. B., Britt W. J., 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis171:1115–1121. doi: 10.1093/infdis/171.5.11157751685
5. Lilleri D, Kabanova A., Revello M. G., Percivalle E., Sarasini A., Genini E, Sallusto F., Lanzavecchia A., Corti D., Gerna G, 2013. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS ONE. 8:e59863. doi: 10.1371/journal.pone.005986323555812
6. Rieder F, Steininger C, 2014. Cytomegalovirus vaccine: phase II clinical trial results. Clin Microbiol Infect20:95–102. doi: 10.1111/1469-0691.1244924283990
7. Adler S. P., Plotkin S. A., Gonczol E., Cadoz M., Meric C., Wang J. B., Dellamonica P., Best A. M. Zahradnik J., Pincus S., Berencsi K., Cox W. I, Gyulai Z, 1999. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis180: 843–846. doi: 10.1086/31495110438376
8. Berensci K, Gyulai Z, Gonczol E., Pincus S., Cox W. I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., Plotkin S., 2001. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis183: 1171–1179. doi: 10.1086/31968011262198
9. Smith L. R., Wlock M. K., Chaplin J. A., Gerber M., Rolland A. P., 2013. Clinical development of a cytomegalovirus DNA vaccine: from product concept to a pivotal phase 3 trial. Vaccines. 398–414. doi: 10.3390/vaccines104039826344340
10. Nigro G, Adler S, La Torre R, Best AM, 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 353: 1350–1362. 16192480
11. Revello M. G., Lazzarotto T., Guerra B, Spinillo A., Ferrazzi E., Kustermann A., Guaschino S., Vergani P., Todros T., Frusca T., Arossa A., Furione M., Rognoni V., Rizzo N., Gabrielli L., Klersy C., Gerna G, 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 370: 1316–1326. doi: 10.1056/NEJMoa131021424693891
12. Leviton M. P., Lacayo J. C., Choi K. Y., Hernandez-Alvarado N., Wey A., Schleiss M. R., 2013. An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model. Clin Dev Immunol2013:906948. doi: 10.1155/2013/90694824000289
13. Schleiss M. R., Lacayo J. C., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J. D., Smith J. F, 2007. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis195:789–798. doi: 10.1086/51198217299708
14. Berstein D. I., Reap E. A., Katen K., Watson A., Smith K., Norberg P., Olmsted R. A., Hoeper A., Morris J., Negri S., Maughan M. F., Chulay J. D, 2010. Randomized, double-blind, Phase I trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 28:484–493. doi: 10.1016/j.vaccine.2009.09.135
15. Wloch M. K., Smith L. R., Boutsaboualoy S., Reyes S., Han C., Kehler J., Smith H. D., Selk L., Nakamura R., Brown J. M., Marbury T., Wald A., Rolland A., Kaslow D., Evans T., Boeckh M, 2008. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis197:1634–1642. doi: 10.1086/58838518444883
16. Jacobson M. A., Adler S. P., Sinclair E., Black D., Smith A., Chu A., Moss R. B., Wloch M. K, 2009. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 27:1540–1548. doi: 10.1016/j.vaccine.2009.01.00619168107
17. Chatterjee A, Harrison C. J., Britt W. J., Bewtra C, 2001. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs. J Infect Dis183:1547–1553. doi: 10.1086/32071411343203
18. Auerback M. R., Yan D., Vij R., Hongo J., Nakamura G., Vernes J., Meng Y. G., Lein S., Chan P., Ross J., Carano R., Deng R., Lewin-Koh N., Xu M., Feierbach B, 2014. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog. 10:e1004060. doi: 10.1371/journal.ppat.100406024722349
19. Bialas K. M., Tanaka T., Tran D., Varner V., de la Rosa E. C., Chiuppesi F., Wussow F., Kattenhorn L., Macri S., Kunz E. L., Estroff J. A., Kirchherr J., Yue Y., Fan Q., Lauc M., O’Connor D. H., Hall A., Xavier A., Diamond D. J., Barry P. A., Kaur A., Permar S. R, 2015. Maternal CD4+ T cells protect against severe congenital CMV disease in a novel nonhuman primate model of placental CMV transmission. Proc Natl Acad Sci U S A;112(44):13645–50. 26483473
20. Tarantal A. F., Salamat M. S., Britt W. J., Luciw P. A., Henrickx A. G., Barry P. A, 1998. Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta). J Infect Dis177:446–450. doi: 10.1086/5142069466534